View ValuationMediPal Holdings 将来の成長Future 基準チェック /16MediPal Holdings利益と収益がそれぞれ年間3.8%と2.7%増加すると予測されています。EPS は年間 増加すると予想されています。自己資本利益率は 3 年後に6.8% 4.5%なると予測されています。主要情報3.8%収益成長率4.52%EPS成長率Healthcare 収益成長17.4%収益成長率2.7%将来の株主資本利益率6.80%アナリストカバレッジLow最終更新日12 Aug 2026今後の成長に関する最新情報お知らせ • Jul 15Medipal Holdings Corporation Revises Consolidated Earnings Guidance for the Fiscal Year Ending March 31, 2027MediPal Holdings Corporation revised consolidated earnings guidance for the fiscal year ending March 31, 2027. For the year, the company expects net sales of ¥3,944,000 million, operating profit of ¥53,500 million compared to previous guidance of ¥55,000 million, profit attributable to owners of parent of ¥43,000 million compared to previous guidance of ¥39,000 million and earnings per share of ¥210.06 compared to previous guidance of ¥190.52. The tender offer conducted by MEDIPAL for the shares of PALTAC CORPORATION was completed on July 7, 2026. Going forward, MEDIPAL will proceed with squeeze- out procedures to make PALTAC a wholly owned subsidiary, which is scheduled for around August 2026. As a result, the portion of PALTAC's profit that was previously attributable to non-controlling interests will become entirely attributable to MEDIPAL, contributing to an increase in profit attributable to owners of parent. Meanwhile, temporary related expenses, including consulting fees associated with the tender offer, are expected to be incurred as general and administrative expenses, while financial expenses such as interest on funding will be recognized as non-operating expenses.すべての更新を表示Recent updatesお知らせ • Jul 15Medipal Holdings Corporation Revises Consolidated Earnings Guidance for the Fiscal Year Ending March 31, 2027MediPal Holdings Corporation revised consolidated earnings guidance for the fiscal year ending March 31, 2027. For the year, the company expects net sales of ¥3,944,000 million, operating profit of ¥53,500 million compared to previous guidance of ¥55,000 million, profit attributable to owners of parent of ¥43,000 million compared to previous guidance of ¥39,000 million and earnings per share of ¥210.06 compared to previous guidance of ¥190.52. The tender offer conducted by MEDIPAL for the shares of PALTAC CORPORATION was completed on July 7, 2026. Going forward, MEDIPAL will proceed with squeeze- out procedures to make PALTAC a wholly owned subsidiary, which is scheduled for around August 2026. As a result, the portion of PALTAC's profit that was previously attributable to non-controlling interests will become entirely attributable to MEDIPAL, contributing to an increase in profit attributable to owners of parent. Meanwhile, temporary related expenses, including consulting fees associated with the tender offer, are expected to be incurred as general and administrative expenses, while financial expenses such as interest on funding will be recognized as non-operating expenses.お知らせ • Jul 09MediPal Holdings Corporation (TSE:7459) completed the acquisition of remaining 47.60% stake in Paltac Corporation (TSE:8283) from group of shareholders.MediPal Holdings Corporation (TSE:7459) proposed to acquire remaining 47.60% stake in Paltac Corporation (TSE:8283) from group of shareholders for approximately ¥190 billion on May 8, 2026. A cash consideration of ¥192.46 billion valued at ¥6650 per share will be paid by MediPal Holdings Corporation. As part of consideration, ¥192.46 billion is paid towards common equity of Paltac Corporation. Upon completion, MediPal Holdings Corporation will hold 100% stake of Paltac Corporation. The transaction will be funded by means of loans from Mizuho Bank, Ltd. As of June 19, 2026, S.T. Corporation has resolved to tender its 339,000 shares. The transaction is subject to minimum tender. The Board of Directors of Paltac Corporation formed a special committee for the transaction. The expected completion of the transaction is on July 7, 2026. Nishimura & Asahi acted as legal advisor for MediPal Holdings Corporation. Nomura Securities Co., Ltd. acted as financial advisor for MediPal Holdings Corporation. Oh-Ebashi LPC & Partners acted as legal advisor for Paltac Corporation. Daiwa Securities Co. Ltd. acted as financial advisor for Paltac Corporation. Anderson Mori & Tomotsune acted as legal advisor for Paltac Corporation. Plutus Consulting Co., Ltd. acted as financial advisor and fairness opinion provider for Paltac Corporation. MediPal Holdings Corporation (TSE:7459) completed the acquisition of remaining 47.60% stake in Paltac Corporation (TSE:8283) from group of shareholders on July 7, 2026. A total of 24,466,104 shares were tendered, which was above the minimum number of shares to be purchased (8,676,100 shares). MediPal Holdings Corporation plans to implement a series of procedures to make the Tender Offeror the sole shareholder of Paltac Corporation (the “Squeeze-out Procedures”). Upon completion, the shares of Paltac Corporation will be delisted from the Prime Market of the Tokyo Stock Exchange.お知らせ • Jun 27MediPal Holdings Corporation to Report Q1, 2027 Results on Aug 05, 2026MediPal Holdings Corporation announced that they will report Q1, 2027 results on Aug 05, 2026お知らせ • May 14MediPal Holdings Corporation, Annual General Meeting, Jun 24, 2026MediPal Holdings Corporation, Annual General Meeting, Jun 24, 2026.お知らせ • May 13MediPal Holdings Corporation (TSE:7459) proposed to acquire remaining 47.60% stake in Paltac Corporation (TSE:8283) from State Street Bank & Trust Company 505103, JP Morgan Chase Bank 385632, State Street Bank & Trust Company 505001 Obayashi Group, BNYM AS Agt CLTS 10 Percent, BBH For Fidelity Low-Priced STOCK Fund and NORTHERN TRUST CO. (AVFC) RE FIDELITY FUNDS for approximately ¥190 billion.MediPal Holdings Corporation (TSE:7459) proposed to acquire remaining 47.60% stake in Paltac Corporation (TSE:8283) from State Street Bank & Trust Company 505103, JP Morgan Chase Bank 385632, State Street Bank & Trust Company 505001 Obayashi Group, BNYM AS Agt CLTS 10 Percent, BBH For Fidelity Low-Priced STOCK Fund and NORTHERN TRUST CO. (AVFC) RE FIDELITY FUNDS for approximately ¥190 billion on May 8, 2026. A cash consideration of ¥192.46 billion valued at ¥6650 per share will be paid by MediPal Holdings Corporation. As part of consideration, ¥192.46 billion is paid towards common equity of Paltac Corporation. Upon completion, MediPal Holdings Corporation will hold 100% stake of Paltac Corporation. The transaction will be funded by means of loans from Mizuho Bank, Ltd. The transaction is subject to minimum tender. The Board of Directors of Paltac Corporation formed a special committee for the transaction. The expected completion of the transaction is on July 7, 2026. Nishimura & Asahi acted as legal advisor for MediPal Holdings Corporation. Nomura Securities Co., Ltd. acted as financial advisor for MediPal Holdings Corporation. Oh-Ebashi LPC & Partners acted as legal advisor for Paltac Corporation. Daiwa Securities Co. Ltd. acted as financial advisor for Paltac Corporation. Anderson Mori & Tomotsune acted as legal advisor for Paltac Corporation. Plutus Consulting Co., Ltd. acted as financial advisor and fairness opinion provider for Paltac Corporation.お知らせ • May 10MediPal Holdings Corporation to Report Fiscal Year 2026 Results on May 14, 2026MediPal Holdings Corporation announced that they will report fiscal year 2026 results on May 14, 2026お知らせ • Feb 05Nippon Life Insurance Company completed the acquisition of 52.34% stake in Medical Data Vision Co., Ltd. (TSE:3902) from MediPal Holdings Corporation (TSE:7459), Hiroyuki Iwasaki and others for ¥33.9 billion.Nippon Life Insurance Company proposed to acquire 62.19% stake in Medical Data Vision Co., Ltd. (TSE:3902) from MediPal Holdings Corporation (TSE:7459), Hiroyuki Iwasaki and others for ¥40.4 billion on December 15, 2025. A cash consideration valued at ¥1 per right and valued at ¥1693 per share will be paid by Nippon Life Insurance Company. As part of consideration, ¥3706 is paid towards Fourth Series of Share Acquisition Rights, ¥1400 is paid towards Fifth Series of Share Acquisition Rights and ¥40.4 billion is paid towards common equity of Medical Data Vision Co., Ltd. In a related transaction, Nippon Life Insurance Company is acquiring 37.81% stake in Medical Data Vision Co., Ltd. from SBI Holdings, Inc. Upon completion of the transactions, Nippon Life Insurance Company will hold 100% stake in Medical Data Vision Co., Ltd. The transaction is subject to minimum tender. The expected completion of the transaction is February 3, 2026. SMBC Nikko Securities Inc. acted as tender offer agent. Nippon Life Insurance Company completed the acquisition of 52.34% stake in Medical Data Vision Co., Ltd. (TSE:3902) from MediPal Holdings Corporation (TSE:7459), Hiroyuki Iwasaki and others on February 3, 2025.お知らせ • Dec 16Nippon Life Insurance Company proposed to acquire 62.19% stake in Medical Data Vision Co., Ltd. (TSE:3902) from MediPal Holdings Corporation (TSE:7459), Hiroyuki Iwasaki and others for ¥40.4 billion.Nippon Life Insurance Company proposed to acquire 62.19% stake in Medical Data Vision Co., Ltd. (TSE:3902) from MediPal Holdings Corporation (TSE:7459), Hiroyuki Iwasaki and others for ¥40.4 billion on December 15, 2025. A cash consideration valued at ¥1 per right and valued at ¥1693 per share will be paid by Nippon Life Insurance Company. As part of consideration, ¥3706 is paid towards Fourth Series of Share Acquisition Rights, ¥1400 is paid towards Fifth Series of Share Acquisition Rights and ¥40.4 billion is paid towards common equity of Medical Data Vision Co., Ltd. In a related transaction, Nippon Life Insurance Company is acquiring 37.81% stake in Medical Data Vision Co., Ltd. from SBI Holdings, Inc. Upon completion of the transactions, Nippon Life Insurance Company will hold 100% stake in Medical Data Vision Co., Ltd. The transaction is subject to minimum tender. The expected completion of the transaction is February 3, 2026. SMBC Nikko Securities Inc. acted as tender offer agent.お知らせ • Nov 29MediPal Holdings Corporation to Report Q3, 2026 Results on Feb 09, 2026MediPal Holdings Corporation announced that they will report Q3, 2026 results on Feb 09, 2026お知らせ • Sep 30Medipal Holdings Corporation and JCR Pharmaceuticals Co., Ltd. Announce Notice of Orphan Drug Designation for JR-446 for Mucopolysaccharidosis Type IIIB by Ministry of Health, Labour and Welfare of JapanMEDIPAL HOLDINGS Corporation and JCR Pharmaceuticals Co., Ltd. announced that the Ministry of Health, Labour and Welfare of Japan has granted orphan drug designation to JR-446, an investigational drug for the treatment of MPS IIIB (MPS IIIB or Sanfilippo syndrome type B). JCR was granted orphan drug designation for the treatment of MPS II by the U.S. Food and Drug Administration (FDA) in April 2025, and by the European Commission (EC) in June 2025. MPS IIIB affects an estimated 500 to 1,000 individuals worldwide, causing severe central nervous system (CNS) symptoms. Despite the dire need, there are currently no approved treatments available for this condition. JR-446, developed using JCR's proprietary J-Brain Cargo®? technology, has shown promising non-clinical results in addressing the CNS symptoms of this challenging disorder, and it is currently being studied in a Phase I/II trial that is being conducted in Japan (JR-446-101) under a collaboration agreement between the two companies. In September 2023, MEDIPAL and JCR entered into a licensing agreement in which MEDIPAL will commercialize JR-446 for MPS IIIB outside of Japan. In addition, MEDIPAL will support JCR in the clinical development of JR-446 in Japan, including the distribution of investigational drugs, disease awareness, and clinical trial advancement. Both companies remain committed to developing a therapy for patients with MPS IIIB as swiftly as possible. Under the orphan drug designation system, the Ministry of Health, Labour & Welfare of Japan takes special measures to support and promote research activities for the development of drugs for rare diseases. Drugs satisfaction the following criteria may be designated as orphan drugs: they are targeting a condition with an incidence of fewer than 50,000 patients in Japan, or their intended use is for the treatment of a designated intractable disease. The drugs should be indicated for the treatment of serious diseases including difficult-to-treat diseases for which there are high unmet medical needs, such as there is no approved medicinal product or higher efficacy, or safety is expected compared with an approved medicinal product. Moreover, the application for orphan drug designation needs to have enough resources and plans for development of its product as an orphan drug in Japan. Mucopolysaccharidosis type IIIB, or Sanfilippo Syndrome type B, is an autosomal recessive disease caused by pathogenic mutations in the NAGLU gene, encoding a lysosomal enzyme involved in the degradation of heparan sulfate. With the accumulation of heparan sulfate in the central nervous system in the brain, individuals with this condition present rapid neurological decline, including sleep disorders, loss of speech, and behavioral changes, which may significantly affect the quality of life of patients and their families.お知らせ • Aug 27MediPal Holdings Corporation to Report Q2, 2026 Results on Nov 05, 2025MediPal Holdings Corporation announced that they will report Q2, 2026 results on Nov 05, 2025お知らせ • Jun 29MediPal Holdings Corporation to Report Q1, 2026 Results on Aug 05, 2025MediPal Holdings Corporation announced that they will report Q1, 2026 results on Aug 05, 2025お知らせ • May 15MediPal Holdings Corporation (TSE:7459) announces an Equity Buyback for 4,000,000 shares, representing 1.92% for ¥8,000 million.MediPal Holdings Corporation (TSE:7459) announces a share repurchase program. Under the program, the company will repurchase up to 4,000,000 shares, representing 1.92% of its issued share capital (excluding treasury stock), for ¥8,000 million. The purpose of the program is to improve capital efficiency through shareholder returns. The repurchased shares will be cancelled. The program will run until October 31, 2025. As of April 30, 2025, the company had 207,950,180 shares in issue (excluding treasury stock) and 11,275,862 shares in treasury.お知らせ • May 13MediPal Holdings Corporation, Annual General Meeting, Jun 25, 2025MediPal Holdings Corporation, Annual General Meeting, Jun 25, 2025.お知らせ • Mar 01MediPal Holdings Corporation to Report Fiscal Year 2025 Results on May 13, 2025MediPal Holdings Corporation announced that they will report fiscal year 2025 results on May 13, 2025お知らせ • Dec 03+ 1 more updateMediPal Holdings Corporation to Report Q3, 2025 Results on Feb 06, 2025MediPal Holdings Corporation announced that they will report Q3, 2025 results on Feb 06, 2025お知らせ • Aug 27MediPal Holdings Corporation to Report Q2, 2025 Results on Nov 01, 2024MediPal Holdings Corporation announced that they will report Q2, 2025 results on Nov 01, 2024お知らせ • Jul 01MEDIPAL Holdings Corporation and JCR Pharmaceuticals Co., Ltd. Announce Completion of Clinical Trial Notification Process in Japan for Phase I/II Study of JR-446 for Mucopolysaccharidosis Type IIIBMediPal Holdings Corporation and JCR Pharmaceuticals Co., Ltd. announced the completion of the regulatory review by the Pharmaceuticals and Medical Devices Agency (PMDA) for the clinical trial notification for the phase I/II study of JR-446, a blood-brain barrier-penetrating a-N-acetylglucosaminidase, for the treatment of mucopolysaccharidosis type IIIB (MPS IIIB; Sanfilippo syndrome type B), a devastating and ultra-rare lysosomal storage disorder. MPS IIIB affects an estimated 500 to 1,000 individuals worldwide, causing severe central nervous system symptoms. Despite the dire need, there are currently no approved treatments available for this condition. JR-446, developed using JCR's proprietary J-Brain Cargo technology, has shown promising preclinical results in addressing the symptoms of this challenging disorder. In September 2023, MEDIPAL and JCR secured a license to commercialize JR-446 overseas and partnered to develop and commercialize it in Japan, targeting MPS IIIB2. With the regulatory review now complete, company plan to start the clinical trial in Japan in the first half of fiscal 2024 (April to September). This collaboration highlights the commitment of MEDIPAL and JCR to pioneer treatments for ultrarare diseases. By advancing therapies like JR-446, company aim to bring hope to patients and their families, while enhancing corporate value and contributing to a society where everyone can live with physical and mental well-being.お知らせ • Jun 06MediPal Holdings Corporation to Report Q1, 2025 Results on Aug 01, 2024MediPal Holdings Corporation announced that they will report Q1, 2025 results on Aug 01, 2024お知らせ • Jun 01MediPal Holdings Corporation (TSE:7459) completed the acquisition of PreMedica Inc. from Noritsu Koki Co., Ltd. (TSE:7744).MediPal Holdings Corporation (TSE:7459) agreed to acquire PreMedica Inc. from Noritsu Koki Co., Ltd. (TSE:7744) for ¥3.8 billion on April 30, 2024. Transaction has already been approved by Noritsu Koki's board of director's. Transaction is expected to complete on May 31, 2024.MediPal Holdings Corporation (TSE:7459) completed the acquisition of PreMedica Inc. from Noritsu Koki Co., Ltd. (TSE:7744) on May 31, 2024.お知らせ • May 16MediPal Holdings Corporation, Annual General Meeting, Jun 25, 2024MediPal Holdings Corporation, Annual General Meeting, Jun 25, 2024.お知らせ • May 15MediPal Holdings Corporation (TSE:7459) announces an Equity Buyback for 2,500,000 shares, representing 1.19% for ¥5,000 million.MediPal Holdings Corporation (TSE:7459) announces a share repurchase program. Under the program, the company will repurchase up to 2,500,000 shares, representing 1.19% of its issued share capital (excluding treasury stock), for ¥5,000 million. The purpose of the program is to improve capital efficiency through shareholder returns. The repurchased shares will be cancelled. The program will run until August 30, 2024. As of April 30, 2024, the company had 210,016,973 shares in issue (excluding treasury stock) and 11,274,369 shares in treasury.お知らせ • May 01MediPal Holdings Corporation (TSE:7459) agreed to acquire PreMedica Inc. from Noritsu Koki Co., Ltd. (TSE:7744) for ¥3.8 billion.MediPal Holdings Corporation (TSE:7459) agreed to acquire PreMedica Inc. from Noritsu Koki Co., Ltd. (TSE:7744) for ¥3.8 billion on April 30, 2024. Transaction has already been approved by Noritsu Koki's board of director's. Transaction is expected to complete on May 31, 2024.お知らせ • Mar 02MediPal Holdings Corporation to Report Fiscal Year 2024 Results on May 14, 2024MediPal Holdings Corporation announced that they will report fiscal year 2024 results on May 14, 2024お知らせ • Nov 27MediPal Holdings Corporation to Report Q3, 2024 Results on Feb 05, 2024MediPal Holdings Corporation announced that they will report Q3, 2024 results on Feb 05, 2024お知らせ • Aug 30MediPal Holdings Corporation to Report Q2, 2024 Results on Nov 02, 2023MediPal Holdings Corporation announced that they will report Q2, 2024 results on Nov 02, 2023お知らせ • May 31MediPal Holdings Corporation to Report Q1, 2024 Results on Aug 02, 2023MediPal Holdings Corporation announced that they will report Q1, 2024 results on Aug 02, 2023お知らせ • May 14MediPal Holdings Corporation, Annual General Meeting, Jun 27, 2023MediPal Holdings Corporation, Annual General Meeting, Jun 27, 2023.お知らせ • Nov 30MediPal Holdings Corporation to Report Q3, 2023 Results on Feb 01, 2023MediPal Holdings Corporation announced that they will report Q3, 2023 results on Feb 01, 2023業績と収益の成長予測OTCPK:MEPD.F - アナリストの将来予測と過去の財務データ ( )JPY Millions日付収益収益フリー・キャッシュフロー営業活動によるキャッシュ平均アナリスト数3/31/20294,137,83746,49762,000N/A33/31/20284,041,70144,92551,596N/A53/31/20273,932,22344,877117,000N/A56/30/20263,861,69846,594N/AN/AN/A3/31/20263,817,35442,53436,86546,552N/A12/31/20253,775,82341,455N/AN/AN/A9/30/20253,744,21840,64234,13444,228N/A6/30/20253,707,17040,857N/AN/AN/A3/31/20253,671,32840,27948,12860,559N/A12/31/20243,650,98949,426N/AN/AN/A9/30/20243,604,41546,04756,72572,460N/A6/30/20243,581,31239,294N/AN/AN/A3/31/20243,558,73241,47442,44861,843N/A12/31/20233,507,50537,244N/AN/AN/A9/30/20233,453,60138,63640,54356,888N/A6/30/20233,408,41741,724N/AN/AN/A3/31/20233,360,00838,8062,64216,146N/A12/31/20223,351,06930,439N/AN/AN/A9/30/20223,333,07328,22211,52326,954N/A6/30/20223,304,37228,248N/AN/AN/A3/31/20223,290,92129,42342,33961,216N/A12/31/20213,279,58336,411N/AN/AN/A9/30/20213,265,95130,52325,25945,124N/A6/30/20213,241,83826,468N/AN/AN/A3/31/20213,211,12523,92618,78034,448N/A12/31/20203,208,23726,682N/AN/AN/A9/30/20203,186,65133,32958,48884,718N/A6/30/20203,236,31537,002N/AN/AN/A3/31/20203,253,07937,968N/A56,917N/A12/31/20193,242,84034,722N/AN/AN/A9/30/20193,253,49535,443N/A33,428N/A6/30/20193,189,61334,116N/AN/AN/A3/31/20193,181,92834,359N/A63,716N/A12/31/20183,178,57834,315N/AN/AN/A9/30/20183,169,34434,122N/A75,079N/A6/30/20183,169,21637,166N/AN/AN/A3/31/20183,146,31434,780N/A63,558N/A12/31/20173,124,72433,199N/AN/AN/A9/30/20173,093,74331,086N/A45,376N/A6/30/20173,072,59726,239N/AN/AN/A3/31/20173,063,90029,011N/A47,954N/A12/31/20163,065,83332,149N/AN/AN/A9/30/20163,072,86832,201N/A53,535N/A6/30/20163,057,50133,965N/AN/AN/A3/31/20163,028,18730,771N/A21,985N/A12/31/20152,995,21028,449N/AN/AN/A9/30/20152,953,70726,052N/A25,185N/Aもっと見るアナリストによる今後の成長予測収入対貯蓄率: MEPD.Fの予測収益成長率 (年間3.8% ) は 貯蓄率 ( 3.7% ) を上回っています。収益対市場: MEPD.Fの収益 ( 3.8% ) US市場 ( 16.9% ) よりも低い成長が予測されています。高成長収益: MEPD.Fの収益は増加すると予測されていますが、大幅には増加しません。収益対市場: MEPD.Fの収益 ( 2.7% ) US市場 ( 12.9% ) よりも低い成長が予測されています。高い収益成長: MEPD.Fの収益 ( 2.7% ) 20%よりも低い成長が予測されています。一株当たり利益成長率予想将来の株主資本利益率将来のROE: MEPD.Fの 自己資本利益率 は、3年後には低くなると予測されています ( 6.8 %)。成長企業の発掘7D1Y7D1Y7D1YHealthcare 業界の高成長企業。View Past Performance企業分析と財務データの現状データ最終更新日（UTC時間）企業分析2026/08/21 13:24終値2026/06/01 00:00収益2026/06/30年間収益2026/03/31データソース企業分析に使用したデータはS&P Global Market Intelligence LLC のものです。本レポートを作成するための分析モデルでは、以下のデータを使用しています。データは正規化されているため、ソースが利用可能になるまでに時間がかかる場合があります。パッケージデータタイムフレーム米国ソース例会社財務10年損益計算書キャッシュ・フロー計算書貸借対照表SECフォーム10-KSECフォーム10-Qアナリストのコンセンサス予想+プラス3年予想財務アナリストの目標株価アナリストリサーチレポートBlue Matrix市場価格30年株価配当、分割、措置ICEマーケットデータSECフォームS-1所有権10年トップ株主インサイダー取引SECフォーム4SECフォーム13Dマネジメント10年リーダーシップ・チーム取締役会SECフォーム10-KSECフォームDEF 14A主な進展10年会社からのお知らせSECフォーム8-K* 米国証券を対象とした例であり、非米国証券については、同等の規制書式および情報源を使用。特に断りのない限り、すべての財務データは1年ごとの期間に基づいていますが、四半期ごとに更新されます。これは、TTM（Trailing Twelve Month）またはLTM（Last Twelve Month）データとして知られています。詳細はこちら。分析モデルとスノーフレークこのレポートを生成するために使用した分析モデルの詳細は、当社のGitHubページでご覧いただけます。また、レポートの活用方法に関するガイドやYouTubeのチュートリアルも用意しています。シンプリー・ウォールストリート分析モデルを設計・構築した世界トップクラスのチームについてご紹介します。業界およびセクターの指標私たちの業界とセクションの指標は、Simply Wall Stによって6時間ごとに計算されます。アナリスト筋MediPal Holdings Corporation 5 これらのアナリストのうち、弊社レポートのインプットとして使用した売上高または利益の予想を提出したのは、 。アナリストの投稿は一日中更新されます。9 アナリスト機関Atsushi SekiBarclaysRitsuo WatanabeBofA Global ResearchHidemaru YamaguchiCitigroup Inc6 その他のアナリストを表示
お知らせ • Jul 15Medipal Holdings Corporation Revises Consolidated Earnings Guidance for the Fiscal Year Ending March 31, 2027MediPal Holdings Corporation revised consolidated earnings guidance for the fiscal year ending March 31, 2027. For the year, the company expects net sales of ¥3,944,000 million, operating profit of ¥53,500 million compared to previous guidance of ¥55,000 million, profit attributable to owners of parent of ¥43,000 million compared to previous guidance of ¥39,000 million and earnings per share of ¥210.06 compared to previous guidance of ¥190.52. The tender offer conducted by MEDIPAL for the shares of PALTAC CORPORATION was completed on July 7, 2026. Going forward, MEDIPAL will proceed with squeeze- out procedures to make PALTAC a wholly owned subsidiary, which is scheduled for around August 2026. As a result, the portion of PALTAC's profit that was previously attributable to non-controlling interests will become entirely attributable to MEDIPAL, contributing to an increase in profit attributable to owners of parent. Meanwhile, temporary related expenses, including consulting fees associated with the tender offer, are expected to be incurred as general and administrative expenses, while financial expenses such as interest on funding will be recognized as non-operating expenses.
お知らせ • Jul 15Medipal Holdings Corporation Revises Consolidated Earnings Guidance for the Fiscal Year Ending March 31, 2027MediPal Holdings Corporation revised consolidated earnings guidance for the fiscal year ending March 31, 2027. For the year, the company expects net sales of ¥3,944,000 million, operating profit of ¥53,500 million compared to previous guidance of ¥55,000 million, profit attributable to owners of parent of ¥43,000 million compared to previous guidance of ¥39,000 million and earnings per share of ¥210.06 compared to previous guidance of ¥190.52. The tender offer conducted by MEDIPAL for the shares of PALTAC CORPORATION was completed on July 7, 2026. Going forward, MEDIPAL will proceed with squeeze- out procedures to make PALTAC a wholly owned subsidiary, which is scheduled for around August 2026. As a result, the portion of PALTAC's profit that was previously attributable to non-controlling interests will become entirely attributable to MEDIPAL, contributing to an increase in profit attributable to owners of parent. Meanwhile, temporary related expenses, including consulting fees associated with the tender offer, are expected to be incurred as general and administrative expenses, while financial expenses such as interest on funding will be recognized as non-operating expenses.
お知らせ • Jul 09MediPal Holdings Corporation (TSE:7459) completed the acquisition of remaining 47.60% stake in Paltac Corporation (TSE:8283) from group of shareholders.MediPal Holdings Corporation (TSE:7459) proposed to acquire remaining 47.60% stake in Paltac Corporation (TSE:8283) from group of shareholders for approximately ¥190 billion on May 8, 2026. A cash consideration of ¥192.46 billion valued at ¥6650 per share will be paid by MediPal Holdings Corporation. As part of consideration, ¥192.46 billion is paid towards common equity of Paltac Corporation. Upon completion, MediPal Holdings Corporation will hold 100% stake of Paltac Corporation. The transaction will be funded by means of loans from Mizuho Bank, Ltd. As of June 19, 2026, S.T. Corporation has resolved to tender its 339,000 shares. The transaction is subject to minimum tender. The Board of Directors of Paltac Corporation formed a special committee for the transaction. The expected completion of the transaction is on July 7, 2026. Nishimura & Asahi acted as legal advisor for MediPal Holdings Corporation. Nomura Securities Co., Ltd. acted as financial advisor for MediPal Holdings Corporation. Oh-Ebashi LPC & Partners acted as legal advisor for Paltac Corporation. Daiwa Securities Co. Ltd. acted as financial advisor for Paltac Corporation. Anderson Mori & Tomotsune acted as legal advisor for Paltac Corporation. Plutus Consulting Co., Ltd. acted as financial advisor and fairness opinion provider for Paltac Corporation. MediPal Holdings Corporation (TSE:7459) completed the acquisition of remaining 47.60% stake in Paltac Corporation (TSE:8283) from group of shareholders on July 7, 2026. A total of 24,466,104 shares were tendered, which was above the minimum number of shares to be purchased (8,676,100 shares). MediPal Holdings Corporation plans to implement a series of procedures to make the Tender Offeror the sole shareholder of Paltac Corporation (the “Squeeze-out Procedures”). Upon completion, the shares of Paltac Corporation will be delisted from the Prime Market of the Tokyo Stock Exchange.
お知らせ • Jun 27MediPal Holdings Corporation to Report Q1, 2027 Results on Aug 05, 2026MediPal Holdings Corporation announced that they will report Q1, 2027 results on Aug 05, 2026
お知らせ • May 14MediPal Holdings Corporation, Annual General Meeting, Jun 24, 2026MediPal Holdings Corporation, Annual General Meeting, Jun 24, 2026.
お知らせ • May 13MediPal Holdings Corporation (TSE:7459) proposed to acquire remaining 47.60% stake in Paltac Corporation (TSE:8283) from State Street Bank & Trust Company 505103, JP Morgan Chase Bank 385632, State Street Bank & Trust Company 505001 Obayashi Group, BNYM AS Agt CLTS 10 Percent, BBH For Fidelity Low-Priced STOCK Fund and NORTHERN TRUST CO. (AVFC) RE FIDELITY FUNDS for approximately ¥190 billion.MediPal Holdings Corporation (TSE:7459) proposed to acquire remaining 47.60% stake in Paltac Corporation (TSE:8283) from State Street Bank & Trust Company 505103, JP Morgan Chase Bank 385632, State Street Bank & Trust Company 505001 Obayashi Group, BNYM AS Agt CLTS 10 Percent, BBH For Fidelity Low-Priced STOCK Fund and NORTHERN TRUST CO. (AVFC) RE FIDELITY FUNDS for approximately ¥190 billion on May 8, 2026. A cash consideration of ¥192.46 billion valued at ¥6650 per share will be paid by MediPal Holdings Corporation. As part of consideration, ¥192.46 billion is paid towards common equity of Paltac Corporation. Upon completion, MediPal Holdings Corporation will hold 100% stake of Paltac Corporation. The transaction will be funded by means of loans from Mizuho Bank, Ltd. The transaction is subject to minimum tender. The Board of Directors of Paltac Corporation formed a special committee for the transaction. The expected completion of the transaction is on July 7, 2026. Nishimura & Asahi acted as legal advisor for MediPal Holdings Corporation. Nomura Securities Co., Ltd. acted as financial advisor for MediPal Holdings Corporation. Oh-Ebashi LPC & Partners acted as legal advisor for Paltac Corporation. Daiwa Securities Co. Ltd. acted as financial advisor for Paltac Corporation. Anderson Mori & Tomotsune acted as legal advisor for Paltac Corporation. Plutus Consulting Co., Ltd. acted as financial advisor and fairness opinion provider for Paltac Corporation.
お知らせ • May 10MediPal Holdings Corporation to Report Fiscal Year 2026 Results on May 14, 2026MediPal Holdings Corporation announced that they will report fiscal year 2026 results on May 14, 2026
お知らせ • Feb 05Nippon Life Insurance Company completed the acquisition of 52.34% stake in Medical Data Vision Co., Ltd. (TSE:3902) from MediPal Holdings Corporation (TSE:7459), Hiroyuki Iwasaki and others for ¥33.9 billion.Nippon Life Insurance Company proposed to acquire 62.19% stake in Medical Data Vision Co., Ltd. (TSE:3902) from MediPal Holdings Corporation (TSE:7459), Hiroyuki Iwasaki and others for ¥40.4 billion on December 15, 2025. A cash consideration valued at ¥1 per right and valued at ¥1693 per share will be paid by Nippon Life Insurance Company. As part of consideration, ¥3706 is paid towards Fourth Series of Share Acquisition Rights, ¥1400 is paid towards Fifth Series of Share Acquisition Rights and ¥40.4 billion is paid towards common equity of Medical Data Vision Co., Ltd. In a related transaction, Nippon Life Insurance Company is acquiring 37.81% stake in Medical Data Vision Co., Ltd. from SBI Holdings, Inc. Upon completion of the transactions, Nippon Life Insurance Company will hold 100% stake in Medical Data Vision Co., Ltd. The transaction is subject to minimum tender. The expected completion of the transaction is February 3, 2026. SMBC Nikko Securities Inc. acted as tender offer agent. Nippon Life Insurance Company completed the acquisition of 52.34% stake in Medical Data Vision Co., Ltd. (TSE:3902) from MediPal Holdings Corporation (TSE:7459), Hiroyuki Iwasaki and others on February 3, 2025.
お知らせ • Dec 16Nippon Life Insurance Company proposed to acquire 62.19% stake in Medical Data Vision Co., Ltd. (TSE:3902) from MediPal Holdings Corporation (TSE:7459), Hiroyuki Iwasaki and others for ¥40.4 billion.Nippon Life Insurance Company proposed to acquire 62.19% stake in Medical Data Vision Co., Ltd. (TSE:3902) from MediPal Holdings Corporation (TSE:7459), Hiroyuki Iwasaki and others for ¥40.4 billion on December 15, 2025. A cash consideration valued at ¥1 per right and valued at ¥1693 per share will be paid by Nippon Life Insurance Company. As part of consideration, ¥3706 is paid towards Fourth Series of Share Acquisition Rights, ¥1400 is paid towards Fifth Series of Share Acquisition Rights and ¥40.4 billion is paid towards common equity of Medical Data Vision Co., Ltd. In a related transaction, Nippon Life Insurance Company is acquiring 37.81% stake in Medical Data Vision Co., Ltd. from SBI Holdings, Inc. Upon completion of the transactions, Nippon Life Insurance Company will hold 100% stake in Medical Data Vision Co., Ltd. The transaction is subject to minimum tender. The expected completion of the transaction is February 3, 2026. SMBC Nikko Securities Inc. acted as tender offer agent.
お知らせ • Nov 29MediPal Holdings Corporation to Report Q3, 2026 Results on Feb 09, 2026MediPal Holdings Corporation announced that they will report Q3, 2026 results on Feb 09, 2026
お知らせ • Sep 30Medipal Holdings Corporation and JCR Pharmaceuticals Co., Ltd. Announce Notice of Orphan Drug Designation for JR-446 for Mucopolysaccharidosis Type IIIB by Ministry of Health, Labour and Welfare of JapanMEDIPAL HOLDINGS Corporation and JCR Pharmaceuticals Co., Ltd. announced that the Ministry of Health, Labour and Welfare of Japan has granted orphan drug designation to JR-446, an investigational drug for the treatment of MPS IIIB (MPS IIIB or Sanfilippo syndrome type B). JCR was granted orphan drug designation for the treatment of MPS II by the U.S. Food and Drug Administration (FDA) in April 2025, and by the European Commission (EC) in June 2025. MPS IIIB affects an estimated 500 to 1,000 individuals worldwide, causing severe central nervous system (CNS) symptoms. Despite the dire need, there are currently no approved treatments available for this condition. JR-446, developed using JCR's proprietary J-Brain Cargo®? technology, has shown promising non-clinical results in addressing the CNS symptoms of this challenging disorder, and it is currently being studied in a Phase I/II trial that is being conducted in Japan (JR-446-101) under a collaboration agreement between the two companies. In September 2023, MEDIPAL and JCR entered into a licensing agreement in which MEDIPAL will commercialize JR-446 for MPS IIIB outside of Japan. In addition, MEDIPAL will support JCR in the clinical development of JR-446 in Japan, including the distribution of investigational drugs, disease awareness, and clinical trial advancement. Both companies remain committed to developing a therapy for patients with MPS IIIB as swiftly as possible. Under the orphan drug designation system, the Ministry of Health, Labour & Welfare of Japan takes special measures to support and promote research activities for the development of drugs for rare diseases. Drugs satisfaction the following criteria may be designated as orphan drugs: they are targeting a condition with an incidence of fewer than 50,000 patients in Japan, or their intended use is for the treatment of a designated intractable disease. The drugs should be indicated for the treatment of serious diseases including difficult-to-treat diseases for which there are high unmet medical needs, such as there is no approved medicinal product or higher efficacy, or safety is expected compared with an approved medicinal product. Moreover, the application for orphan drug designation needs to have enough resources and plans for development of its product as an orphan drug in Japan. Mucopolysaccharidosis type IIIB, or Sanfilippo Syndrome type B, is an autosomal recessive disease caused by pathogenic mutations in the NAGLU gene, encoding a lysosomal enzyme involved in the degradation of heparan sulfate. With the accumulation of heparan sulfate in the central nervous system in the brain, individuals with this condition present rapid neurological decline, including sleep disorders, loss of speech, and behavioral changes, which may significantly affect the quality of life of patients and their families.
お知らせ • Aug 27MediPal Holdings Corporation to Report Q2, 2026 Results on Nov 05, 2025MediPal Holdings Corporation announced that they will report Q2, 2026 results on Nov 05, 2025
お知らせ • Jun 29MediPal Holdings Corporation to Report Q1, 2026 Results on Aug 05, 2025MediPal Holdings Corporation announced that they will report Q1, 2026 results on Aug 05, 2025
お知らせ • May 15MediPal Holdings Corporation (TSE:7459) announces an Equity Buyback for 4,000,000 shares, representing 1.92% for ¥8,000 million.MediPal Holdings Corporation (TSE:7459) announces a share repurchase program. Under the program, the company will repurchase up to 4,000,000 shares, representing 1.92% of its issued share capital (excluding treasury stock), for ¥8,000 million. The purpose of the program is to improve capital efficiency through shareholder returns. The repurchased shares will be cancelled. The program will run until October 31, 2025. As of April 30, 2025, the company had 207,950,180 shares in issue (excluding treasury stock) and 11,275,862 shares in treasury.
お知らせ • May 13MediPal Holdings Corporation, Annual General Meeting, Jun 25, 2025MediPal Holdings Corporation, Annual General Meeting, Jun 25, 2025.
お知らせ • Mar 01MediPal Holdings Corporation to Report Fiscal Year 2025 Results on May 13, 2025MediPal Holdings Corporation announced that they will report fiscal year 2025 results on May 13, 2025
お知らせ • Dec 03+ 1 more updateMediPal Holdings Corporation to Report Q3, 2025 Results on Feb 06, 2025MediPal Holdings Corporation announced that they will report Q3, 2025 results on Feb 06, 2025
お知らせ • Aug 27MediPal Holdings Corporation to Report Q2, 2025 Results on Nov 01, 2024MediPal Holdings Corporation announced that they will report Q2, 2025 results on Nov 01, 2024
お知らせ • Jul 01MEDIPAL Holdings Corporation and JCR Pharmaceuticals Co., Ltd. Announce Completion of Clinical Trial Notification Process in Japan for Phase I/II Study of JR-446 for Mucopolysaccharidosis Type IIIBMediPal Holdings Corporation and JCR Pharmaceuticals Co., Ltd. announced the completion of the regulatory review by the Pharmaceuticals and Medical Devices Agency (PMDA) for the clinical trial notification for the phase I/II study of JR-446, a blood-brain barrier-penetrating a-N-acetylglucosaminidase, for the treatment of mucopolysaccharidosis type IIIB (MPS IIIB; Sanfilippo syndrome type B), a devastating and ultra-rare lysosomal storage disorder. MPS IIIB affects an estimated 500 to 1,000 individuals worldwide, causing severe central nervous system symptoms. Despite the dire need, there are currently no approved treatments available for this condition. JR-446, developed using JCR's proprietary J-Brain Cargo technology, has shown promising preclinical results in addressing the symptoms of this challenging disorder. In September 2023, MEDIPAL and JCR secured a license to commercialize JR-446 overseas and partnered to develop and commercialize it in Japan, targeting MPS IIIB2. With the regulatory review now complete, company plan to start the clinical trial in Japan in the first half of fiscal 2024 (April to September). This collaboration highlights the commitment of MEDIPAL and JCR to pioneer treatments for ultrarare diseases. By advancing therapies like JR-446, company aim to bring hope to patients and their families, while enhancing corporate value and contributing to a society where everyone can live with physical and mental well-being.
お知らせ • Jun 06MediPal Holdings Corporation to Report Q1, 2025 Results on Aug 01, 2024MediPal Holdings Corporation announced that they will report Q1, 2025 results on Aug 01, 2024
お知らせ • Jun 01MediPal Holdings Corporation (TSE:7459) completed the acquisition of PreMedica Inc. from Noritsu Koki Co., Ltd. (TSE:7744).MediPal Holdings Corporation (TSE:7459) agreed to acquire PreMedica Inc. from Noritsu Koki Co., Ltd. (TSE:7744) for ¥3.8 billion on April 30, 2024. Transaction has already been approved by Noritsu Koki's board of director's. Transaction is expected to complete on May 31, 2024.MediPal Holdings Corporation (TSE:7459) completed the acquisition of PreMedica Inc. from Noritsu Koki Co., Ltd. (TSE:7744) on May 31, 2024.
お知らせ • May 16MediPal Holdings Corporation, Annual General Meeting, Jun 25, 2024MediPal Holdings Corporation, Annual General Meeting, Jun 25, 2024.
お知らせ • May 15MediPal Holdings Corporation (TSE:7459) announces an Equity Buyback for 2,500,000 shares, representing 1.19% for ¥5,000 million.MediPal Holdings Corporation (TSE:7459) announces a share repurchase program. Under the program, the company will repurchase up to 2,500,000 shares, representing 1.19% of its issued share capital (excluding treasury stock), for ¥5,000 million. The purpose of the program is to improve capital efficiency through shareholder returns. The repurchased shares will be cancelled. The program will run until August 30, 2024. As of April 30, 2024, the company had 210,016,973 shares in issue (excluding treasury stock) and 11,274,369 shares in treasury.
お知らせ • May 01MediPal Holdings Corporation (TSE:7459) agreed to acquire PreMedica Inc. from Noritsu Koki Co., Ltd. (TSE:7744) for ¥3.8 billion.MediPal Holdings Corporation (TSE:7459) agreed to acquire PreMedica Inc. from Noritsu Koki Co., Ltd. (TSE:7744) for ¥3.8 billion on April 30, 2024. Transaction has already been approved by Noritsu Koki's board of director's. Transaction is expected to complete on May 31, 2024.
お知らせ • Mar 02MediPal Holdings Corporation to Report Fiscal Year 2024 Results on May 14, 2024MediPal Holdings Corporation announced that they will report fiscal year 2024 results on May 14, 2024
お知らせ • Nov 27MediPal Holdings Corporation to Report Q3, 2024 Results on Feb 05, 2024MediPal Holdings Corporation announced that they will report Q3, 2024 results on Feb 05, 2024
お知らせ • Aug 30MediPal Holdings Corporation to Report Q2, 2024 Results on Nov 02, 2023MediPal Holdings Corporation announced that they will report Q2, 2024 results on Nov 02, 2023
お知らせ • May 31MediPal Holdings Corporation to Report Q1, 2024 Results on Aug 02, 2023MediPal Holdings Corporation announced that they will report Q1, 2024 results on Aug 02, 2023
お知らせ • May 14MediPal Holdings Corporation, Annual General Meeting, Jun 27, 2023MediPal Holdings Corporation, Annual General Meeting, Jun 27, 2023.
お知らせ • Nov 30MediPal Holdings Corporation to Report Q3, 2023 Results on Feb 01, 2023MediPal Holdings Corporation announced that they will report Q3, 2023 results on Feb 01, 2023